pc190723 profile

PC190723: Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	25016417
CHEMBL ID	511201
SCHEMBL ID	2706605
MeSH ID	M0525456

Synonym
CHEMBL511201 ,
3-[(6-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide
9pc ,
951120-33-5
pc-190723
benzamide, 3-((6-chlorothiazolo(5,4-b)pyridin-2-yl)methoxy)-2,6-difluoro-
3-((6-chlorothiazolo(5,4-b)pyridin-2-yl)methoxy)-2,6-difluorobenzamide
7V5K32W934 ,
SCHEMBL2706605
pc 190723
pc190723
unii-7v5k32w934
3-((6-chlorothiazolo[5,4-b]pyridin-2-yl)methoxy)-2,6-difluorobenzamide
bdbm50079356
DTXSID80648429
3-[(6-chlorothiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide
3-[(6-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide
Q27268896
3-({6-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}methoxy)-2,6-difluorobenzamide
CS-0498290
HY-146331

Excerpt	Reference	Relevance
"PC190723 is a fluoride-containing benzamide compound developed as a FtsZ inhibitor that selectively inhibits growth of multidrug resistant Gram-positive bacteria."	( RfiA, a novel PAP2 domain-containing polytopic membrane protein that confers resistance to the FtsZ inhibitor PC190723. An, L; Chen, T; Chen, X; Dyson, P; Facey, P; Ju, F; Li, S; Liu, G; Mullins, JG; Ren, C; Xiao, J; Zhang, B, 2015)	1.35
"PC190723 is an effective bactericidal cell division inhibitor that targets FtsZ in the pathogen Staphylococcus aureus and Bacillus subtilis and does not affect Escherichia coli cells, which apparently binds to a zone equivalent to the binding site of the antitumor drug taxol in tubulin (Haydon, D."	( The antibacterial cell division inhibitor PC190723 is an FtsZ polymer-stabilizing agent that induces filament assembly and condensation. Alonso, D; Andreu, JM; Huecas, S; Llorca, O; Lopez-Rodriguez, ML; Martín-Galiano, AJ; Núñez-Ramírez, R; Ruiz-Avila, LB; Schaffner-Barbero, C, 2010)	1.35

Excerpt	Reference	Relevance
" In staphylococcal growth media, TXY541 converts to PC190723 with a half-life of approximately 8h."	( Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. Kaul, M; LaVoie, EJ; Mark, L; Parhi, AK; Pilch, DS; Zhang, Y, 2013)	0.85
"The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties."	( TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Kaul, M; LaVoie, EJ; Lyu, YL; Mark, L; Parhi, AK; Pawlak, J; Pilch, DS; Saravolatz, LD; Saravolatz, S; Weinstein, MP; Zhang, Y, 2015)	0.65

Excerpt	Reference	Relevance
" In addition, TXY436 was found to be orally bioavailable and associated with significant extravascular distribution."	( An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo. Kaul, M; Lavoie, EJ; Mark, L; Parhi, AK; Pilch, DS; Zhang, Y, 2013)	0.39
"56h and an oral bioavailability of 29."	( Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. Kaul, M; LaVoie, EJ; Mark, L; Parhi, AK; Pilch, DS; Zhang, Y, 2013)	0.6

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cell division protein FtsZ	Bacillus subtilis	Kd	0.1000	0.1000	0.1000	0.1000	AID1811677
Cell division protein FtsZ	Staphylococcus aureus	EC50 (µMol)	4.0000	4.0000	4.0000	4.0000	AID1205864
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cell division protein FtsZ	Bacillus subtilis	Activity	0.1000	0.1000	0.1000	0.1000	AID1811661
Cell division protein FtsZ	Staphylococcus aureus	Activity	0.1000	0.1000	0.1000	0.1000	AID1628127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (144)

Assay ID	Title	Year	Journal	Article
AID1414194	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID1443332	Inhibition of FtsZ in Mycobacterium smegmatis ATCC 607 assessed as growth inhibition at 100 ug per disc after 18 to 24 hrs by paper disc agar diffusion assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Synthesis and antibacterial activity of 3-benzylamide derivatives as FtsZ inhibitors.
AID394518	Antibacterial activity against Bacillus subtilis by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1534161	Inhibition of Staphylococcus aureus N-terminal 6His-tagged FtsZ polymerization expressed in Escherichia coli BL21 (DE3) at 100 uM relative to control	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID394537	Antibacterial activity against Staphylococcus aureus bearing FtsZ G196A mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1326327	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1533843	Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID394546	Antibacterial activity against Staphylococcus aureus Smith ATCC 19636 in CD1 mouse septicemia model assessed as survival at 30 mg/kg, sc after 7 days relative to control	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394520	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850146	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 1720 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1591545	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID394532	Antibacterial activity against Streptococcus pneumoniae by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850161	Inhibition of GFP-tagged FtsZ in Bacillus subtilis 168 assessed as inhibition of z-ring formation at 0.125 ug/ml incubated for 4 hrs by FM 5-96 dye based super-resolution microscopy	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1060729	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.
AID1591560	Bactericidal activity against Staphylococcus aureus ATCC 25923 assessed as 3 log reduction in number of colony forming units incubated for 24 hrs followed by aliquots transfer to tryptic soy agar and grown for 24 hrs	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1850151	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth incubated for 18 hrs in presence of methicillin by checkerboard assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850155	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as FICI incubated for 18 hrs in presence of methicillin by checkerboard assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394547	Antibacterial activity against Staphylococcus aureus Smith ATCC 19636 in CD1 mouse septicemia model assessed as survival at 30 mg/kg, iv after 7 days relative to control	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1060728	Inhibition of Staphylococcus aureus ATCC 29213 FtsZ-mediated cell division phenotype	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.
AID1850171	Inhibition of Staphylococcus aureus FtsZ polymerization assessed as increase in GTPase activity at 16 ug/ml incubated for 40 mins in presence of GTP by malachite green phosphate assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394526	Antibacterial activity against Staphylococcus saprophyticus by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1811667	Antimicrobial activity against Bacillus subtilis 168 assessed as inhibition of bacterial growth by CLSI based broth macrodilution method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1811666	Antimicrobial activity against methicillin resistant Staphylococcus aureus Mu50 assessed as inhibition of bacterial growth by CLSI based broth macrodilution method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1591562	Bactericidal activity against penicillin-resistant Staphylococcus aureus clinical isolate assessed as 3 log reduction in number of colony forming units incubated for 24 hrs followed by aliquots transfer to tryptic soy agar and grown for 24 hrs	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1534182	Synergistic antibacterial activity against Staphylococcus aureus ATCC BAA-41 at 1 to 16 times MIC in presence of methicillin after 21 hrs by time kill assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID394548	Antibacterial activity against Staphylococcus aureus Smith ATCC 19636 in sc dosed CD1 mouse septicemia model assessed as survival after 7 days	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1677802	Antibacterial activity against Pseudomonas aeruginosa ATCC27853 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1201502	Antimicrobial activity against Staphylococcus	2015	European journal of medicinal chemistry, May-05, Volume: 95	Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.
AID1591540	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1811663	Binding affinity to Staphylococcus aureus FtsZ polymer assessed as dissociation constant by fluorescence anisotropy analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1850166	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth at 8 ug/ml incubated for 24 hrs by time-kill assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394533	Antifungal activity against Saccharomyces cerevisiae by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394519	Antibacterial activity against Staphylococcus aureus by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394550	Antibacterial activity against Staphylococcus aureus Smith ATCC 19636 in ip dosed CD1 mouse septicemia model assessed as survival administered 1 hr postinfection measured after 7 days	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591561	Bactericidal activity against Staphylococcus aureus ATCC 43300 assessed as 3 log reduction in number of colony forming units incubated for 24 hrs followed by aliquots transfer to tryptic soy agar and grown for 24 hrs	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1850159	Antibacterial activity against Bacillus subtilis 168 assessed as cell length at 0.5 ug/ml incubated for 4 hrs by phase-contrast microscopy	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1677804	Antibacterial activity against Staphylococcus aureus clinical isolate incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1591544	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1374407	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
AID394555	Inhibition of cell division in Staphylococcus aureus ATCC 29213 assessed as enlargement of cells at 2 ug/ml within 2 hrs by phase contrast microscopy	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1677809	Antibacterial activity against Bacillus subtilis ATCC9372 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1414189	Antibacterial activity against Bacillus pumilus CMCC63202 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID1443327	Inhibition of FtsZ in Staphylococcus aureus ATCC 6538P assessed as ratio of diameter of zone inhibition of test compound to diameter of zone inhibition of cephaloridine at 100 ug per disc after 18 to 24 hrs by paper disc agar diffusion assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Synthesis and antibacterial activity of 3-benzylamide derivatives as FtsZ inhibitors.
AID1850141	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1534168	Inhibition of Staphylococcus aureus N-terminal 6His-tagged FtsZ GTPase expressed in Escherichia coli BL21 (DE3) at 50 uM relative to control	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID394523	Antibacterial activity against Staphylococcus haemolyticus by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1811661	Binding affinity to Bacillus subtilis FtsZ polymer assessed as dissociation constant by fluorescence anisotropy analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1628127	Activation of Staphylococcus aureus FtsZ assessed as increase in GTPase activity by malachite green assay	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Targeting the Bacterial Division Protein FtsZ.
AID1326326	Antibacterial activity against Bacillus subtilis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1205864	Activation of Staphylococcus aureus FtsZ GTPase activity	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Synthesis and Evaluation of Quinazolines as Inhibitors of the Bacterial Cell Division Protein FtsZ.
AID1534180	Antibacterial activity against Staphylococcus aureus ATCC BAA-41 at 116 times MIC after 24 hrs by time kill assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID394528	Antibacterial activity against Enterococcus faecalis by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1414190	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID394542	Antibacterial activity against Bacillus subtilis bearing FtsZ G196A mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591543	Antibacterial activity against Staphylococcus aureus clinical isolate incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1677805	Antibacterial activity against penicillin-resistant Staphylococcus aureus incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID394551	Inhibition of Staphylococcus aureus FtsZ GTPase activity	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394554	Inhibition of cell division in Staphylococcus aureus ATCC 29213 assessed as enlargement of cells at 2 ug/ml by phase contrast microscopy	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1443331	Inhibition of FtsZ in Bacillus subtilis ATCC 6633 assessed as growth inhibition at 100 ug per disc after 18 to 24 hrs by paper disc agar diffusion assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Synthesis and antibacterial activity of 3-benzylamide derivatives as FtsZ inhibitors.
AID1414192	Antibacterial activity against clinical isolate of penicillin-resistant Staphylococcus aureus after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID394560	Enhancement of bovine brain tubulin polymerization at 64 ug/ml	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394522	Antibacterial activity against Staphylococcus epidermidis by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394539	Antibacterial activity against Staphylococcus aureus bearing FtsZ N263K mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850164	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth at 2 ug/ml incubated for 24 hrs by time-kill assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850163	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth at 1 ug/ml incubated for 24 hrs by time-kill assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1326329	Inhibition of Staphylococcus aureus FtsZ GTPase activity	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID394556	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in cell viability at 2 ug/ml within 2 hrs by serial dilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591548	Ratio of MBC for penicillin-resistant Staphylococcus aureus clinical isolate to MIC for penicillin-resistant Staphylococcus aureus clinical isolate	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID394553	Inhibition of cell division in Bacillus subtilis 168 assessed as elongation of cells at 2 ug/ml by phase contrast microscopy	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591550	Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as log reduction in viable bacterial count at 2 ug/ml incubated for 24 hrs by time-kill curve assay	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1533844	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1850168	Ratio of MBC for bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 to MIC for antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 41	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1811677	Displacement of free fluorescent probe from inter domain cleft of stabilized Bacillus subtilis FtsZ assessed as dissociation constant in presence of GMPCPP by fluorescence anisotropy analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1414191	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID1850143	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1120513	Antimicrobial activity against Bacillus subtilis subsp. subtilis str. 168 after 18 hrs by macro-dilution method	2013	MedChemComm, Jan-01, Volume: 4, Issue:1	Inhibitors of bacterial tubulin target bacterial membranes
AID1677803	Antibacterial activity against Escherichia coli ATCC25922 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1414216	Antibacterial activity against Staphylococcus aureus	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID1811676	Antimicrobial activity against methicillin resistant Staphylococcus aureus Mu50 assessed as inhibition of cell division incubated for 1.5 hrs by phase contrast microscopic analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1677807	Antibacterial activity against Staphylococcus aureus ATCC25923 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1374404	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
AID394531	Antibacterial activity against Pseudomonas aeruginosa by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394534	Cytotoxicity against human HepG2 cells	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394559	Inhibition of bovine brain tubulin polymerization at 64 ug/ml	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850156	Antibacterial activity against Bacillus subtilis 168 assessed as cell elongation at 0.5 ug/ml incubated for 4 hrs by phase-contrast microscopy	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850170	Inhibition of Staphylococcus aureus FtsZ polymerization assessed as increase in GTPase activity at 8 ug/ml incubated for 40 mins in presence of GTP by malachite green phosphate assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850165	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth at 4 ug/ml incubated for 24 hrs by time-kill assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850138	Antibacterial activity against Bacillus subtilis 168 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two-fold serial dilution assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394527	Antibacterial activity against Staphylococcus warneri by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1414188	Antibacterial activity against Bacillus subtilis ATCC 9372 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID394540	Antibacterial activity against Staphylococcus aureus bearing FtsZ G266S mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850169	Inhibition of Staphylococcus aureus FtsZ polymerization assessed as increase in GTPase activity at 1 ug/ml incubated for 40 mins in presence of GTP by malachite green phosphate assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1591547	Ratio of MBC for methicillin-resistant Staphylococcus aureus ATCC 43300 to MIC for methicillin-resistant Staphylococcus aureus ATCC 43300	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1201479	Inhibition of Staphylococcus aureus FtsZ GTPase activity	2015	European journal of medicinal chemistry, May-05, Volume: 95	Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.
AID394538	Antibacterial activity against Staphylococcus aureus bearing FtsZ V214F mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850144	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1850173	Inhibition of Staphylococcus aureus FtsZ polymerization assessed as increase in GTPase activity at 5 to 20 ug/ml incubated for 40 mins in presence of GTP by malachite green phosphate assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1374403	Antibacterial activity against Bacillus subtilis ATCC 9372 after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
AID1677808	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC43300 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1628116	Antimicrobial activity against Staphylococcus aureus	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Targeting the Bacterial Division Protein FtsZ.
AID1374408	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
AID394549	Antibacterial activity against Staphylococcus aureus Smith ATCC 19636 in iv dosed CD1 mouse septicemia model assessed as survival after 7 days	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850139	Antibacterial activity against Staphylococcus aureus 29213 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1534169	Inhibition of Staphylococcus aureus N-terminal 6His-tagged FtsZ GTPase expressed in Escherichia coli BL21 (DE3) at 100 uM relative to control	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1850142	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 44 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1326328	Antibacterial activity against multi-drug resistant Staphylococcus aureus	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID394529	Antibacterial activity against Escherichia coli by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591541	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1850140	Antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1120510	Induction of transmembrane potential loss in Bacillus subtilis subsp. subtilis str. 168 at 1 times MIC pre-treated for 5 mins and measured 15 mins post dye addition by DiOC2 dye based flow cytometry	2013	MedChemComm, Jan-01, Volume: 4, Issue:1	Inhibitors of bacterial tubulin target bacterial membranes
AID1591538	Antibacterial activity against Bacillus subtilis ATCC 9372 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1120509	Increase in bacterial membrane permeability in Bacillus subtilis subsp. subtilis str. 168 at 1 times MIC pre-treated for 5 mins and measured 30 mins post dye addition by propidium iodide dye based flow cytometry	2013	MedChemComm, Jan-01, Volume: 4, Issue:1	Inhibitors of bacterial tubulin target bacterial membranes
AID1533847	Bactericidal activity against Staphylococcus aureus ATCC BAA-41 assessed as log reduction in bacterial growth at 2 to 4 times MIC up to 7 hrs by time kill assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1591539	Antibacterial activity against Bacillus pumilus CMCC63202 incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID394545	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as logarithmic reduction in viable cell numbers at >= MIC after 24 hrs	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1850145	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based two fold serial dilution method	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394530	Antibacterial activity against Haemophilus influenzae by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394543	Antibacterial activity against Bacillus subtilis bearing FtsZ V307R mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1534181	Synergistic bactericidal activity against Staphylococcus aureus ATCC BAA-41 at 1 to 16 times MIC in presence of methicillin up to 24 hrs by time kill assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1850147	Synergistic antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth incubated for 18 hrs in presence of PMBN by checkerboard assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID394525	Antibacterial activity against Staphylococcus lugdunensis by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394535	Antibacterial activity against Staphylococcus aureus bearing FtsZ R191P mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1811670	Bactericidal activity against Staphylococcus aureus assessed as reduction in colony forming units	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID394541	Antibacterial activity against Bacillus subtilis bearing FtsZ A47P mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1591546	Ratio of MBC for Staphylococcus aureus ATCC 25923 to MIC for Staphylococcus aureus ATCC 25923	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID1591542	Antibacterial activity against penicillin-resistant Staphylococcus aureus clinical isolate incubated for 24 hrs by CLSI protocol based broth microdilution method	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
AID394552	Inhibition of GFP-FtsZ localization in Bacillus subtilis 2020 assessed as protein mislocalization to assemble into cytokinetic ring at 8 ug/ml by florescence microscopy	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1326337	Half life in iv dosed BALB/c mouse administered 1 hr after ABT addition by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1120500	Induction of membrane associated proteins mislocalization in Bacillus subtilis subsp. subtilis str. 168 assessed as reduction in GFP-MinD protein localization by fluorescence assay	2013	MedChemComm, Jan-01, Volume: 4, Issue:1	Inhibitors of bacterial tubulin target bacterial membranes
AID1677806	Antibacterial activity against Bacillus pumilus CMCC63202 incubated for 24 hrs by CLSI-based broth microdilution method	2020	Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21	Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
AID1534167	Inhibition of Staphylococcus aureus N-terminal 6His-tagged FtsZ GTPase expressed in Escherichia coli BL21 (DE3) at 30 uM relative to control	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1850167	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA 41 assessed as inhibition of bacterial growth incubated for 24 hrs by time-kill assay	2022	RSC medicinal chemistry, Jan-27, Volume: 13, Issue:1	Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism.
AID1533846	Selective index, ratio of IC50 for mouse L929 cells to MIC for Staphylococcus aureus ATCC 29213	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1374406	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
AID394536	Antibacterial activity against Staphylococcus aureus bearing FtsZ G193D mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1326330	Toxicity in mouse infected with Staphylococcus aureus assessed as survival at 30 mg/kg, iv or po	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID394544	Antibacterial activity against Bacillus subtilis bearing FtsZ V307H mutant by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID394521	Antibacterial activity against multidrug-resistant Staphylococcus aureus by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1060727	Antibacterial activity against Staphylococcus aureus harboring FtsZ G196A mutant by broth microdilution method	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.
AID394524	Antibacterial activity against Staphylococcus hominis by broth microdilution method	2008	Science (New York, N.Y.), Sep-19, Volume: 321, Issue:5896	An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.
AID1414193	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by broth microdilution based CLSI method	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.
AID1533845	Cytotoxicity against mouse L929 cells by MTS assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor.
AID1811675	Antimicrobial activity against Bacillus subtilis 168 assessed as inhibition of cell division incubated for 1.5 hrs by phase contrast microscopic analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery.
AID1374405	Antibacterial activity against penicillin-resistant Staphylococcus aureus after 24 hrs by broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5	Substitution of terminal amide with 1H-1,2,3-triazole: Identification of unexpected class of potent antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (5.26)	29.6817
2010's	31 (81.58)	24.3611
2020's	5 (13.16)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (7.89%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (92.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
coumarin 2H-chromen-2-one: coumarin derivative	3.23	1	coumarins	fluorescent dye; human metabolite; plant metabolite
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.52	2	benzamides
berberine [no description available]	3.71	2	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.08	1	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.9	3	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
dapi DAPI: RN given refers to parent cpd.	3.21	1	indoles	fluorochrome
dichlorophen Dichlorophen: Nontoxic laxative vermicide effective for taenia infestation. It tends to produce colic and nausea. It is also used as a veterinary fungicide, anthelmintic, and antiprotozoan. (From Merck, 11th ed.)	2.08	1	bridged diphenyl fungicide; diarylmethane
sanguinarine benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.	2.08	1	alkaloid antibiotic; benzophenanthridine alkaloid; botanical anti-fungal agent
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	2.89	3	penicillin allergen; penicillin	antibacterial drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	2.21	1	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
thiazoles [no description available]	4.62	24	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	3.69	2	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
1,4-benzodioxan 1,4-benzodioxan: structure in first source	2.11	1
Berberine chloride (TN) [no description available]	4.14	2	organic molecular entity
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.63	2	cyclic ketone; erythromycin
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.82	3	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.21	1	penicillin allergen; penicillin	antibacterial drug
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.04	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	3.21	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
trichlorophene trichlorophene: contains 20 carbon atoms; do not confuse with trichlorophene as name for trichloro derivs of 2,2'-methylenebisphenol (contain 13 carbon atoms)	2.08	1
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.61	2	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
2,6-difluorobenzamide 2,6-difluorobenzamide: structure given in first source	2.11	1
totarol totarol: structure given in first source; isolated from the bark of Podocarpus nagi	3.6	2	diterpenoid	metabolite
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.17	1
3-methoxybenzamide [no description available]	2.48	2
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.07	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.07	1	beta-lactam antibiotic allergen; beta-lactam
dichamanetin dichamanetin: structure in first source	3.21	1	diarylheptanoid	metabolite
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.21	1	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
linezolid [no description available]	3.25	5	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	3.23	1	cinnamic acid	plant metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	3.69	2	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	3.23	1	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	4.97	4	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
trans-4-coumaric acid hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.	3.23	1	4-coumaric acid	food component; mouse metabolite; plant metabolite
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	3.23	1	caffeic acid	geroprotector; mouse metabolite
3-(3,4-dimethoxyphenyl)propenoic acid 3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.	3.23	1	methoxycinnamic acid
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	3.23	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	3.23	1	cinnamate ester; tannin	food component; plant metabolite
led209 LED209: structure in first source	2.04	1
scopoletin [no description available]	3.23	1	hydroxycoumarin	plant growth regulator; plant metabolite
daphnetin [no description available]	3.23	1	hydroxycoumarin
7-hydroxycoumarin 7-oxycoumarin: derivatives have anti-oxidant properties. umbelliferone : A hydroxycoumarin that is coumarin substituted by a hydroxy group ay position 7.	3.23	1	hydroxycoumarin	fluorescent probe; food component; plant metabolite
menaquinone 6 menaquinone 6: RN given refers to (all-E)-isomer	2.04	1
cefuroxime [no description available]	2.53	2	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
pai 039 tiplaxtinin: inhibitor of plasminogen activator inhibitor-1	2.31	1	indole-3-acetic acids
cp 91149 CP 91149: inhibits liver glycogen phosphorylase; structure in first source	2.41	1
cp-673,451 CP-673,451: is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase; structure in first source	2.41	1	aminoquinoline
uridine diphosphate n-acetylmuramic acid Uridine Diphosphate N-Acetylmuramic Acid: A nucleoside diphosphate sugar which is formed from UDP-N-acetylglucosamine and phosphoenolpyruvate. It serves as the building block upon which peptidoglycan is formed.. UDP-N-acetyl-alpha-D-muramate(3-) : A UDP-N-acetyl-D-muramate(3-) in which the anomeric centre of the pyranose fragment has alpha-configuration.	2.17	1	UDP-N-acetylmuramate(3-)
pf-04691502 [no description available]	2.41	1
pf 04929113 [no description available]	2.41	1
chrysophaentin a chrysophaentin A: structure in first source	4.76	3
pf-4708671 [no description available]	2.41	1
pf-5274857 1-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source	2.41	1
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide 2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide: a probe for bromo and extra C-terminal domain proteins; structure in first source	2.41	1	quinazolines
daptomycin [no description available]	2.11	1
guanosine diphosphate Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.	2.77	3	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.49	2	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine 5'-(alpha,beta-methylene)triphosphate guanosine 5'-(alpha,beta-methylene)triphosphate: enhances microtubule nucleation	2.31	1

Condition	Relationship Strength	Studies
Infections, Staphylococcal [description not available]	3.47	7
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	3.47	7
Bacterial Disease [description not available]	3.68	3
Bacterial Infections Infections by bacteria, general or unspecified.	3.68	3
Bacterial Infections, Gram-Positive [description not available]	2.15	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	2.15	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.07	1
Polyploid [description not available]	2.07	1

pc190723

Description

Cross-References

Synonyms (21)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Protein Targets (2)

Activation Measurements

Other Measurements

Bioassays (144)

Research

Studies (38)

Market Indicators

Research Demand Index: 22.25

Study Types

pc190723

Description

Cross-References

Synonyms (21)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Protein Targets (2)

Activation Measurements

Other Measurements

Bioassays (144)

Research

Studies (38)

Market Indicators

Research Demand Index: 22.25

Study Types

Related Drugs (59)

Related Conditions (8)